Detalhe da pesquisa
1.
Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
Blood
; 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38754046
2.
Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.
Br J Haematol
; 197(2): 207-211, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35170759
3.
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects.
Br J Clin Pharmacol
; 88(10): 4573-4584, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35466438
4.
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Lancet
; 395(10232): 1278-1291, 2020 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32305093
5.
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Cancer
; 126(20): 4485-4497, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32757302
6.
Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations.
Blood
; 139(22): 3340-3344, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35377939
7.
Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis.
Future Oncol
; 14(22): 2265-2277, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29569483
8.
The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact.
Haematologica
; 107(6): 1460-1465, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35172559
9.
p85ß regulatory subunit of class IA PI3 kinase negatively regulates mast cell growth, maturation, and leukemogenesis.
Blood
; 119(17): 3951-61, 2012 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-22378847
10.
Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT.
Blood
; 120(13): 2669-78, 2012 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-22806893
11.
The PI3K pathway drives the maturation of mast cells via microphthalmia transcription factor.
Blood
; 118(13): 3459-69, 2011 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-21791431
12.
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.
Ther Adv Hematol
; 14: 20406207231173489, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37273420
13.
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.
Clin Cancer Res
; 29(17): 3301-3312, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37364001
14.
p85alpha regulates osteoblast differentiation by cross-talking with the MAPK pathway.
J Biol Chem
; 286(15): 13512-21, 2011 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21324896
15.
Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors.
Clin Pharmacol Drug Dev
; 11(11): 1294-1307, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36029150
16.
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
Clin Cancer Res
; 28(5): 903-914, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34862248
17.
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis.
J Vis Exp
; (169)2021 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33818572
18.
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
Cancer Discov
; 10(3): 394-405, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31915195
19.
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
J Immunother Cancer
; 8(1)2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32114502
20.
Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression.
Clin Cancer Res
; 26(22): 5852-5859, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32820015